BioCentury | Feb 26, 2021
Distillery Therapeutics

Sphingosine receptor agonist identified for cervical cancer, sarcoma

...M. et al. Cell Chem. Biol.; published online Feb. 8, 2021doi:10.1016/j.chembiol.2021.01.004CONTACT: Masatoshi Hagiwara, Kyoto University, Kyoto, Japanemail: hagiwara.masatoshi.8c@kyoto-u.ac.jp Claire Quang Kyoto University Sphingosine...
BioCentury | Sep 29, 2020
Distillery Therapeutics

Small molecule kinase inhibitor for cystic fibrosis with splicing mutation

...Biol.; published online Sept. 8, 2020doi:10.1016/j.chembiol.2020.08.013CONTACT: Masahiko Ajiro, Kyoto University, Kyoto...
...Japanemail: ajiro.masahiko.6e@kyoto-u.ac.jp CONTACT: Masatoshi Hagiwara, same affiliation as aboveemail: hagiwara.masatoshi.8c@kyoto-u.ac.jp Claire Quang Kyoto University Dual-specificity...
BioCentury | Jan 11, 2020
Targets & Mechanisms

Colitis-associated somatic mutations yield new colorectal cancer target

...mutations were therefore tumorigenic changes. In a December paper in Nature , a group from Kyoto University...
...in UC experience divergent selective pressures during subsequent tumor development. Study author Seishi Ogawa, a Kyoto University...
...can be positively or negatively selected depending on the nature of selective pressure." Seishi Ogawa, Kyoto University...
BioCentury | Nov 18, 2019

Tyrosine kinase inhibitors for the treatment of pemphigus

...Sept. 30, 2019 doi:10.1038/s41467-019-12232-3 CONTACT: Gyohei Egawa, Kyoto University, Kyoto, Japan email: gyohei@kuhp.kyoto-u.ac.jp CONTACT: Kenji Kabashima, Kyoto University...
...kaba@kuhp.kyoto-u.ac.jp Claire Quang Gleevac, Gleevec, Glivec, imatinib mesylate (QTI571, CGP 57148B, Ruvise, STI-571) Agency for Science Technology and Research Kyoto University Stem...
BioCentury | Oct 31, 2019
Preclinical News

Oct. 31 Preclinical Quick Takes: Beam licenses tech from Prime Medicine; plus BioVersys, Astellas-Kyoto University and more

...$5 million in milestones. Converting inflammatory T cells to Tregs Astellas Pharma Inc. (Tokyo:4503) and Kyoto University...
...cells. The CDK8/CDK19 inhibitor suppressed autoimmune and allergic immune responses in animal models. Astellas and Kyoto University...
BioCentury | Jul 26, 2019
Product Development

Takeda's deals paint a picture of a turnaround in action

...that space. In 2015, Takeda, the Center for iPS Cell Research and Application (CiRA) and Kyoto University...
...Ltd., London, U.K. Genmab A/S (CSE:GEN; Pink:GMXAY), Copenhagen, Denmark GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Kyoto University...
...protein 173 Allison Johnson, Senior Writer Adimab LLC Codiak BioSciences Inc. Curadev Pharma Pvt. Ltd. Fujifilm Holdings Corp. GammaDelta Therapeutics Ltd. Genmab A/S Kyoto University Molecular...
BioCentury | Jul 20, 2019
Clinical News

July 19 Clinical Quick Takes: Polyphor closes Phase III murepavadin trials; plus Takeda and Alector

...develop and commercialize a novel induced pluripotent stem cell-derived CAR T cell therapy (iCART) from Kyoto University’s...
...are the first iPS cell program from the collaboration to be transferred to Takeda (see "Kyoto University...
BioCentury | Jul 19, 2019
Product Development

Why GammaDelta would do its Takeda build-to-buy all over again

...has announced other cell therapy partnerships with Japanese CAR T cell company Noile-Immune Biotech Inc., Kyoto University’s...
...Biotechnologies GmbH, Tuebingen, Germany Incysus Therapeutics Inc., New York, N.Y. King’s College London, London, U.K. Kyoto University...
BioCentury | Mar 19, 2019
Distillery Therapeutics

Inhibiting SATB1 in Th17 cells for multiple sclerosis

...Sakaguchi, Kyoto University, Kyoto, Japan email :shimon@ifrec.osaka-u.ac.jp CONTACT: Keiji Hirota, Osaka University, Osaka, Japan email: hkeiji@infront.kyoto-u.ac.jp Claire Quang Kyoto University Osaka...
BioCentury | Mar 1, 2019
Translation in Brief

Targeting pathogenic Th17 cells

...as multiple sclerosis, psoriasis and rheumatoid arthritis. This month, researchers at University of Florida and Kyoto University...
...mice with normal SATB1 levels. Senior author Keiji Hirota, a professor of pharmaceutical sciences at Kyoto University...
Items per page:
1 - 10 of 127
BioCentury | Feb 26, 2021
Distillery Therapeutics

Sphingosine receptor agonist identified for cervical cancer, sarcoma

...M. et al. Cell Chem. Biol.; published online Feb. 8, 2021doi:10.1016/j.chembiol.2021.01.004CONTACT: Masatoshi Hagiwara, Kyoto University, Kyoto, Japanemail: hagiwara.masatoshi.8c@kyoto-u.ac.jp Claire Quang Kyoto University Sphingosine...
BioCentury | Sep 29, 2020
Distillery Therapeutics

Small molecule kinase inhibitor for cystic fibrosis with splicing mutation

...Biol.; published online Sept. 8, 2020doi:10.1016/j.chembiol.2020.08.013CONTACT: Masahiko Ajiro, Kyoto University, Kyoto...
...Japanemail: ajiro.masahiko.6e@kyoto-u.ac.jp CONTACT: Masatoshi Hagiwara, same affiliation as aboveemail: hagiwara.masatoshi.8c@kyoto-u.ac.jp Claire Quang Kyoto University Dual-specificity...
BioCentury | Jan 11, 2020
Targets & Mechanisms

Colitis-associated somatic mutations yield new colorectal cancer target

...mutations were therefore tumorigenic changes. In a December paper in Nature , a group from Kyoto University...
...in UC experience divergent selective pressures during subsequent tumor development. Study author Seishi Ogawa, a Kyoto University...
...can be positively or negatively selected depending on the nature of selective pressure." Seishi Ogawa, Kyoto University...
BioCentury | Nov 18, 2019

Tyrosine kinase inhibitors for the treatment of pemphigus

...Sept. 30, 2019 doi:10.1038/s41467-019-12232-3 CONTACT: Gyohei Egawa, Kyoto University, Kyoto, Japan email: gyohei@kuhp.kyoto-u.ac.jp CONTACT: Kenji Kabashima, Kyoto University...
...kaba@kuhp.kyoto-u.ac.jp Claire Quang Gleevac, Gleevec, Glivec, imatinib mesylate (QTI571, CGP 57148B, Ruvise, STI-571) Agency for Science Technology and Research Kyoto University Stem...
BioCentury | Oct 31, 2019
Preclinical News

Oct. 31 Preclinical Quick Takes: Beam licenses tech from Prime Medicine; plus BioVersys, Astellas-Kyoto University and more

...$5 million in milestones. Converting inflammatory T cells to Tregs Astellas Pharma Inc. (Tokyo:4503) and Kyoto University...
...cells. The CDK8/CDK19 inhibitor suppressed autoimmune and allergic immune responses in animal models. Astellas and Kyoto University...
BioCentury | Jul 26, 2019
Product Development

Takeda's deals paint a picture of a turnaround in action

...that space. In 2015, Takeda, the Center for iPS Cell Research and Application (CiRA) and Kyoto University...
...Ltd., London, U.K. Genmab A/S (CSE:GEN; Pink:GMXAY), Copenhagen, Denmark GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Kyoto University...
...protein 173 Allison Johnson, Senior Writer Adimab LLC Codiak BioSciences Inc. Curadev Pharma Pvt. Ltd. Fujifilm Holdings Corp. GammaDelta Therapeutics Ltd. Genmab A/S Kyoto University Molecular...
BioCentury | Jul 20, 2019
Clinical News

July 19 Clinical Quick Takes: Polyphor closes Phase III murepavadin trials; plus Takeda and Alector

...develop and commercialize a novel induced pluripotent stem cell-derived CAR T cell therapy (iCART) from Kyoto University’s...
...are the first iPS cell program from the collaboration to be transferred to Takeda (see "Kyoto University...
BioCentury | Jul 19, 2019
Product Development

Why GammaDelta would do its Takeda build-to-buy all over again

...has announced other cell therapy partnerships with Japanese CAR T cell company Noile-Immune Biotech Inc., Kyoto University’s...
...Biotechnologies GmbH, Tuebingen, Germany Incysus Therapeutics Inc., New York, N.Y. King’s College London, London, U.K. Kyoto University...
BioCentury | Mar 19, 2019
Distillery Therapeutics

Inhibiting SATB1 in Th17 cells for multiple sclerosis

...Sakaguchi, Kyoto University, Kyoto, Japan email :shimon@ifrec.osaka-u.ac.jp CONTACT: Keiji Hirota, Osaka University, Osaka, Japan email: hkeiji@infront.kyoto-u.ac.jp Claire Quang Kyoto University Osaka...
BioCentury | Mar 1, 2019
Translation in Brief

Targeting pathogenic Th17 cells

...as multiple sclerosis, psoriasis and rheumatoid arthritis. This month, researchers at University of Florida and Kyoto University...
...mice with normal SATB1 levels. Senior author Keiji Hirota, a professor of pharmaceutical sciences at Kyoto University...
Items per page:
1 - 10 of 127